Meeting
2021 ASCO Annual Meeting
Phase 3 trial (GCT3013-05) of epcoritamab versus standard of care in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Authors
Catherine Thieblemont
Assistance Publique & Hôpitaux de Paris (APHP), Hopital Saint-Louis, Hemato-Oncologie, Université de Paris, Paris, France
Catherine Thieblemont , Michael Roost Clausen , Anna Sureda Balari , Pier Luigi Zinzani , Christopher Fox , Su Young Kim , Signe Diness Vindeloev , Pieternella Lugtenburg
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Non-Hodgkin Lymphoma
Clinical Trial Registration Number
NCT04628494
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS7569)
DOI
10.1200/JCO.2021.39.15_suppl.TPS7569
Abstract #
TPS7569
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Epcoritamab (epco) with gemcitabine + oxaliplatin (GemOx) in patients (pts) with relapsed or refractory (R/R) diffuse large B‑cell lymphoma (DLBCL) ineligible for autologous stem cell transplant (ASCT) induces high response rate even in pts failing CAR T therapy.
First Author: Joshua Brody
Poster
2021 ASCO Annual Meeting
A phase III trial evaluating glofitamab in combination with gemcitabine plus oxaliplatin versus rituximab in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
First Author: Mark Hertzberg
Poster
2017 ASCO Annual Meeting
Phase 1b/3 study of avelumab-based combination regimens in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).
First Author: Robert W. Chen